We are live on ! Find out more
XLO icon

Xilio Therapeutics
XLO

36 hedge funds and large institutions have $18.6M invested in Xilio Therapeutics in 2025 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 4

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

15% more capital invested

Capital invested by funds: $16.2M → $18.6M (+$2.43M)

3% more funds holding

Funds holding: 35 → 36 (+1)

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

0.24% less ownership

Funds ownership: 3.28% → 3.04% (-0.24%)

Holders
36
Holders Change
+1
Holders Change %
+2.86%
% of All Funds
0.47%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
4
Increased
6
Reduced
4
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
+$86.2K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$74.8K
3
Squarepoint
Squarepoint
New York
+$66.8K
4
XT
XTX Topco
Cayman Islands
+$29.6K
5
Renaissance Technologies
Renaissance Technologies
New York
+$29K

Top Sellers

Rank Fund Capital Flow
1
GCM
Ghisallo Capital Management
Massachusetts
-$906K
2
Morgan Stanley
Morgan Stanley
New York
-$345K
3
UBS Group
UBS Group
Switzerland
-$162K
4
APP
Avantax Planning Partners
Iowa
-$96.8K
5
Geode Capital Management
Geode Capital Management
Massachusetts
-$29.1K
Name Holding Trade Value Shares
Change 		Change in
Stake
GS
1
Gilead Sciences
California
$7.67M – – –
BCLSI
2
Bain Capital Life Sciences Investors
Massachusetts
$3.85M – – –
MC
3
Merck & Co
New Jersey
$1.25M – – –
TPC
4
Takeda Pharmaceutical Company
Japan
$1.24M – – –
Vanguard Group
5
Vanguard Group
Pennsylvania
$1.06M +$74.8K +7,476 +9%
Morgan Stanley
6
Morgan Stanley
New York
$811K -$345K -34,458 -33%
AIIC
7
AJU IB Investment Company
South Korea
$596K – – –
Fidelity Investments
8
Fidelity Investments
Massachusetts
$431K – – –
Geode Capital Management
9
Geode Capital Management
Massachusetts
$277K -$29.1K -2,906 -11%
Squarepoint
10
Squarepoint
New York
$277K +$66.8K +6,667 +40%
TOCUITCONY
11
Trustees of Columbia University in the City of New York
New York
$210K – – –
Renaissance Technologies
12
Renaissance Technologies
New York
$173K +$29K +2,892 +25%
Balyasny Asset Management
13
Balyasny Asset Management
Illinois
$168K – – –
State Street
14
State Street
Massachusetts
$138K +$86.2K +8,607 +278%
Two Sigma Investments
15
Two Sigma Investments
New York
$74K +$6.98K +697 +13%
XT
16
XTX Topco
Cayman Islands
$64.1K +$29.6K +2,952 +119%
Northern Trust
17
Northern Trust
Illinois
$56.1K – – –
BCM
18
Bridgeway Capital Management
Texas
$47.3K – – –
TSS
19
Two Sigma Securities
New York
$27.1K +$23K +2,295 New
LPL Financial
20
LPL Financial
California
$26.1K – – –
Two Sigma Advisers
21
Two Sigma Advisers
New York
$25K +$21.2K +2,121 New
ACA
22
Aptus Capital Advisors
Alabama
$21.1K – – –
Mariner
23
Mariner
Kansas
$21.1K – – –
HF
24
HRT Financial
New York
$20K +$17.7K +1,767 New
SFG
25
SevenBridge Financial Group
Pennsylvania
$19.3K – – –
1
2

XLO Hedge Fund Activity: Q3 2025 in Review

36 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Xilio Therapeutics (XLO) for Q3 2025, worth a combined $18.6M — up 15% from $16.2M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new XLO positions and 3 closed out — a net gain of 1 holder — while 6 added to existing stakes and 4 trimmed.

The largest buyer was State Street, adding an estimated $86.2K. The largest seller was Ghisallo Capital Management, exiting entirely with an estimated $906K sold.

  • 36 institutional investors held Xilio Therapeutics (XLO) as of Q3 2025, up from 35 in Q2 2025.
  • Funds reported $18.6M of Xilio Therapeutics stock for Q3 2025, up 15% quarter-over-quarter.
  • 4 funds opened new Xilio Therapeutics positions in Q3 2025 and 3 closed out, a net change of +1 holder.
  • The largest Xilio Therapeutics buyer in Q3 2025 was State Street, an estimated $86.2K added.
  • The largest Xilio Therapeutics seller in Q3 2025 was Ghisallo Capital Management, an estimated $906K sold.

Based on aggregated 13F filings for Q3 2025.